Inflammatory bowel disease: a focus on the involvement of dietary fats

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54. e42.
   PubMed Web of Science ®Google Scholar
• Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690–697.
   PubMed Web of Science ®Google Scholar
• Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–165. e2.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423–439.
   PubMed Web of Science ®Google Scholar
• Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57:1185–1191.
   PubMed Web of Science ®Google Scholar
• Li X, Sundquist J, Hemminki K, Sundquist K. Risk of inflammatory bowel disease in first- and second-generation immigrants in Sweden: a nationwide follow-up study. Inflamm Bowel Dis. 2011;17:1784–1791.
   PubMed Web of Science ®Google Scholar
• Tsironi E, Feakins RM, Probert CS, Rampton DS, Phil D. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. Am J Gastroenterol. 2004;99:1749–1755. Erratum in: Am J Gastroenterol. 2005;100:255.
   Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology. 2010;139:1816–1819.
   Google Scholar
• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434.
   PubMed Web of Science ®Google Scholar
• Risek RL, Friend B, Page L. Fat in today’s food supply – level of use and sources. J Am Oil Chem Soc. 1974;51:244–254.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Dietary fat. 2012. Available from: http://www.cdc.gov/nutrition/everyone/basics/fat. Accessed June 4, 2014.
   Google Scholar
• Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479–1484.
   PubMed Web of Science ®Google Scholar
• Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in inflammatory bowel disease. Gut. 1997;40:754–760.
   PubMedGoogle Scholar
• Geerling BJ, Dagnelie PC, Badart-Smook A, Russel MG, Stockbrügger RW, Brummer RJ. Diet as a risk factor in the development of ulcerative colitis. Am J Gastroenterol. 2000;95:1008–1013.
   PubMed Web of Science ®Google Scholar
• IBD in EPIC Study Investigators, Tjonneland A, Overvad K, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut. 2009;58:1606–1611.
   Web of Science ®Google Scholar
• Hart AR, Luben R, Olsen A, et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion. 2008;77:57–64.
   PubMed Web of Science ®Google Scholar
• de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis. Gastroenterology. 2010;139:1912–1917.
   PubMed Web of Science ®Google Scholar
• John S, Luben R, Shrestha SS, Welch A, Khaw KT, Hart AR. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:602–606.
   PubMed Web of Science ®Google Scholar
• Chan SS, Luben R, Olsen A, et al. Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:834–842.
   Google Scholar
• Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut. 2014;63:776–784.
   PubMed Web of Science ®Google Scholar
• Lee TH, Menica-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF. Characterization and biological properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem. 1984;259:2383–2389.
   PubMed Web of Science ®Google Scholar
• Goldman DW, Pickett WC, Goetzl EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Comm. 1983;117:282–288.
   PubMed Web of Science ®Google Scholar
• Rampton D, Collins C. Review article: thromboxanes in inflammatory bowel disease – pathogenic and therapeutic implications. Aliment Pharmacol Ther. 1993;7:357–367.
   PubMed Web of Science ®Google Scholar
• Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75:638–640.
   PubMed Web of Science ®Google Scholar
• Heller A1, Koch T, Schmeck J, van Ackern K. Lipid mediators in inflammatory disorders. Drugs. 1998;55:487–496.
   PubMed Web of Science ®Google Scholar
• Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984;86:453–460.
   PubMed Web of Science ®Google Scholar
• Nishida T, Miwa H, Shigematsu A, Yamamoto M, Iida M, Fujishima M. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut. 1987;28:1002–1007.
   PubMed Web of Science ®Google Scholar
• Calder PC. Fatty acids and immune function: relevance to inflammatory bowel diseases. Rev Immunol. 2009;28:506–534.
   Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349–361.
   PubMed Web of Science ®Google Scholar
• Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids. 2005;73:141–162.
   PubMed Web of Science ®Google Scholar
• Gewirtz AT, Neish AS, Madara JL. Mechanisms of active intestinal inflammation and potential down-regulation via lipoxins. Adv Exp Med Biol. 2002;507:229–236.
   PubMed Web of Science ®Google Scholar
• Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 2006;79:84–92.
   PubMed Web of Science ®Google Scholar
• Vong L, Ferraz JG, Dufton N, et al. Up-regulation of annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One. 2012;7:e39244.
   PubMed Web of Science ®Google Scholar
• Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem. 2012;58:1476–1484.
   PubMed Web of Science ®Google Scholar
• Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest. 2011;121:569–581.
   PubMed Web of Science ®Google Scholar
• Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A. 2005;102:7671–7676.
   PubMed Web of Science ®Google Scholar
• Ishida T, Yoshida M, Arita M, et al. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis. 2010;16:87–95.
   PubMed Web of Science ®Google Scholar
• Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol. 2011;187:1957–1969.
   PubMed Web of Science ®Google Scholar
• Nakamura MT, Nara TY. Structure, function, and dietary regulation of δ6, δ5, and δ9 desaturases. Annu Rev Nutr. 2004;24:345–376.
   PubMed Web of Science ®Google Scholar
• Cho HP, Nakamura MT, Clarke SD. Cloning, expression, and nutritional regulation of the mammalian delta-6 desaturase. J Biol Chem. 1999;274:471–477.
   PubMed Web of Science ®Google Scholar
• Cho HP, Nakamura MT, Clarke SD. Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J Biol Chem. 1999;274:37335–37339.
   PubMed Web of Science ®Google Scholar
• Zietemann V, Kröger J, Enzenbach C, et al. Genetic variation of the FADS1 FADS2 gene cluster and n-6 PUFA composition in erythrocyte membranes in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Br J Nutr. 2010;104:1748–1759.
   Web of Science ®Google Scholar
• Costea I, Mack DR, Lemaitre RN, et al. Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric Crohn’s disease. Gastroenterology. 2014;146:929–931.
   Web of Science ®Google Scholar
• Celinski K, Dworzanski T, Korolczuk A, et al. Activated and inactivated PPARs-γ modulate experimentally induced colitis in rats. Med Sci Monit. 2011;17:BR116–BR124.
   Web of Science ®Google Scholar
• Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997;94:4318–4323.
   PubMed Web of Science ®Google Scholar
• Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999;3:397–403.
   PubMed Web of Science ®Google Scholar
• Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001;22:1379–1383.
   PubMed Web of Science ®Google Scholar
• Chêne G, Dubourdeau M, Balard P, et al. n-3 and n-6 Polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta. 2007;1771:576–589.
   Web of Science ®Google Scholar
• Coyne GS, Kenny DA, Childs S, Sreenan JM, Waters SM. Dietary n-3 polyunsaturated fatty acids alter the expression of genes involved in prostaglandin biosynthesis in the bovine uterus. Theriogenology. 2008;70:772–782.
   Web of Science ®Google Scholar
• Zuo X, Wu Y, Morris JS, et al. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene. 2006;25:1225–1241.
   Web of Science ®Google Scholar
• Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201:1205–1215.
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARγ) heterodimer. A basis for new therapeutic strategies. J Exp Med. 2001;193:827–838.
   PubMed Web of Science ®Google Scholar
• Zhao W, Wang L, Zhang M, et al. Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter. J Biol Chem. 2011;286:5519–5528.
   Web of Science ®Google Scholar
• Noor SO, Ridgway K, Scovell L, et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol. 2010;10:134.
   PubMed Web of Science ®Google Scholar
• Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8:110–120.
   PubMed Web of Science ®Google Scholar
• Thibault R, Blachier F, Darcy-Vrillon B, et al. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis. 2010;16:684–695.
   PubMedGoogle Scholar
• Steed H, Macfarlane GT, Macfarlane S. Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res. 2008;52:898–905.
   Web of Science ®Google Scholar
• Knapp HR, Melly MA. Bactericidal effects of polyunsaturated fatty acids. J Infect Dis. 1986;154:84–94.
   PubMed Web of Science ®Google Scholar
• Pot GK, Majsak-Newman G, Geelen A, et al. Fish consumption and markers of colorectal cancer risk: a multicenter randomized controlled trial. Am J Clin Nutr. 2009;90:354–361.
   PubMed Web of Science ®Google Scholar
• Kuipers RS, Luxwolda MF, Dijck-Brouwer DA, et al. Estimated macronutrient and fatty acid intakes from an East African Paleolithic diet. Br J Nutr. 2010;104:1666–1687.
   Web of Science ®Google Scholar
• Uchiyama K, Nakamura M, Odahara S, et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1696–1707.
   Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.
   PubMed Web of Science ®Google Scholar
• Wright R, Truelove SC. A controlled therapeutic trial of various diets in ulcerative colitis. Br Med J. 1965;2:138–141.
   PubMedGoogle Scholar
• Fell JM. Control of systemic and local inflammation with transforming growth factor beta containing formulas. J Parenter Enteral Nutr. 2005;29:S126–S128.
   PubMed Web of Science ®Google Scholar
• Richman E, Rhodes JM. Review article: evidence-based dietary advice for patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(10):1156–1171.
   PubMed Web of Science ®Google Scholar
• Turner D, Shah PS, Steinhart AH, Zlotkin S, Griffiths AM. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis. 2011;17:336–345.
   PubMed Web of Science ®Google Scholar
• Uchiyama K, Nakamura M, Odahara S, et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1696–1707.
   Web of Science ®Google Scholar